摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

9-cyano-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazin-4-one | 173252-87-4

中文名称
——
中文别名
——
英文名称
9-cyano-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazin-4-one
英文别名
9-cyano-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one;7-oxo-2,5,8-triazatetracyclo[7.7.0.02,6.010,15]hexadeca-1(9),3,5,10,12,14-hexaene-14-carbonitrile
9-cyano-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazin-4-one化学式
CAS
173252-87-4
化学式
C14H8N4O
mdl
——
分子量
248.244
InChiKey
FMQUWOGYKPBKJY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.9
  • 重原子数:
    19
  • 可旋转键数:
    0
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.07
  • 拓扑面积:
    70.7
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    9-cyano-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazin-4-one硫酸 作用下, 反应 2.0h, 生成 9-carboxy-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one
    参考文献:
    名称:
    Synthesis and potent anticonvulsant activities of 4-oxo-imidazo[1,2-a]indeno[1,2-e]pyrazin-8- and -9-carboxylic (acetic) acid AMPA antagonists
    摘要:
    The over-stimulation of excitatory amino acid receptors such as the glutamate AMPA receptor has been suggested to be associated with neurodegenerative disorders. Here we describe an original series of readily water soluble 4-oxo-imidazo[1,2-a] indeno[1,2-e]pyrazin-8- and -9-carboxylic (acetic) acid derivatives. One of these compounds, 4f, exhibited nanomolar binding affinity, potent competitive antagonism at the ionotropic AMPA receptor and a long duration of anticonvulsant activity after administration by parenteral route in vivo. (C) 2000 Elsevier Science Ltd. All rights reserved.
    DOI:
    10.1016/s0960-894x(00)00561-8
  • 作为产物:
    描述:
    1-[(4-cyano-1-oxoindan-2-yl)]imidazole-2-carboxamide溶剂黄146乙醚 作用下, 以 溶剂黄146 为溶剂, 30.0 ℃ 、266.64 kPa 条件下, 反应 22.0h, 以0.4 g of 9-cyano-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one is thus obtained的产率得到9-cyano-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazin-4-one
    参考文献:
    名称:
    5H,10H-imidazo\x9b1,2-a!indeno\x9b1,2-e!pyrazin-4-one derivatives, preparation
    摘要:
    式(I)的化合物,其中R是氢原子或羧基,烷氧羰基,--CO--NR.sub.4 R.sub.5,--PO.sub.3 H.sub.2或--CH.sub.2 OH基团,而R.sub.1是-烷基-NH.sub.2,-烷基-NH--CO--R.sub.3,-烷基-COOR.sub.4,-烷基-CO--NR.sub.5 R.sub.6或--CO--NH--R.sub.7基团。式(I)的化合物具有有价值的药理学特性,并且是α-氨基-3-羟基-5-甲基-4-异恶唑丙酸(AMPA)受体的拮抗剂,也称为quisqualate受体。此外,式(I)的化合物是N-甲基-D-天门冬氨酸(NMDA)受体的非竞争性拮抗剂,更具体地说是NMDA受体甘氨酸调节剂位点的配体。
    公开号:
    US05902803A1
点击查看最新优质反应信息

文献信息

  • 5H,10H-imidazo\x9b1,2-a!indeno\x9b1,2-e!pyrazin-4-one derivatives, preparation
    申请人:Rhone-Poulenc Rorer S.A.
    公开号:US05902803A1
    公开(公告)日:1999-05-11
    Compounds of formula (I), wherein R is a hydrogen atom or a carboxy, alkoxycarbonyl, --CO--NR.sub.4 R.sub.5, --PO.sub.3 H.sub.2 or --CH.sub.2 OH radical, and R.sub.1 is an -alk-NH.sub.2, -alk-NH--CO--R.sub.3, -alk-COOR.sub.4, -alk-CO--NR.sub.5 R.sub.6 or --CO--NH--R.sub.7 radical. The compounds of formula (I) have valuable pharmacological properties and are antagonists of the .alpha.-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor also known as the quisqualate receptor. Furthermore, the compounds of formula (I) are non-competitive antagonists of the N-methyl-D-aspartame (NMDA) receptor and more specifically are ligands for NMDA receptor glycine modulator sites.
    式(I)化合物,其中R为氢原子或羧基、烷氧羰基、--CO--NR₄R₅、--PO₃H₂或--CH₂OH基团,R₁为-烷基-NH₂、-烷基-NH--CO--R₃、-烷基-COOR₄、-烷基-CO--NR₅R₆或--CO--NH--R₇基团。式(I)化合物具有宝贵的药理特性,是α-氨基-3-羟基-5-甲基-4-异噁唑丙酸(AMPA)受体即quisqualate受体的拮抗剂。此外,式(I)化合物是非竞争性N-甲基-D-天冬氨酸(NMDA)受体的拮抗剂,更具体地说是NMDA受体甘氨酸调节位点的配体。
  • Indeno\x9b1,2-E!pyrazine-4-ones, their preparation and the medicaments
    申请人:Rhone-Poulenc Rorer S.A.
    公开号:US05789406A1
    公开(公告)日:1998-08-04
    The compounds of formula (I) ##STR1## wherein R, R.sub.1 and R.sub.2 are defined in the disclosure, and salts thereof. The compounds of formula (I) are non-competitive N-methyl-D-asparate (NMDA) receptor antagonists, particularly NMDA receptor glycine modulation site ligands, and are alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists, this receptor is also known as the quisqualate receptor.
    式(I)的化合物##STR1##其中R、R.sub.1和R.sub.2在披露中有定义,并其盐。式(I)的化合物是非竞争性N-甲基-D-天冬氨酸(NMDA)受体拮抗剂,特别是NMDA受体甘氨酸调节位点配体,并且是α-氨基-3-羟基-5-甲基-4-异恶唑丙酸(AMPA)受体拮抗剂,这种受体也被称为喹氯酸受体。
  • [EN] 5H,10H-IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZIN-4-ONE DERIVATIVES, PREPARATION THEREOF, AND DRUGS CONTAINING SAID DERIVATIVES<br/>[FR] DERIVES DE 5H,10H-IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZIN-4-ONE, LEUR PREPARATION ET LES MEDICAMENTS LES CONTENANT
    申请人:RHONE-POULENC RORER S.A.
    公开号:WO1996031511A1
    公开(公告)日:1996-10-10
    (EN) Compounds of formula (I), wherein R is a hydrogen atom or a carboxy, alkoxycarbonyl, -CO-NR4R5, -PO3H2 or -CH2OH radical, and R1 is an -alk-NH2, -alk-NH-CO-R3, -alk-COOR4, -alk-CO-NR5R6 or -CO-NH-R7 radical. The compounds of formula (I) have valuable pharmacological properties and are antagonists of the $g(a)-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor also known as the quisqualate receptor. Furthermore, the compounds of formula (I) are non-competitive antagonists of the N-methyl-D-aspartate (NMDA) receptor and more specifically are ligands for NMDA receptor glycine modulator sites.(FR) Composés de formule (I), dans laquelle: R représente un atome d'hydrogène ou un radical carboxy, alcoxycarbonyle, -CO-NR4R5, -PO3H2 ou -CH2OH, et R1 représente un radical -alk-NH2, -alk-NH-CO-R3, -alk-COOR4, -alk-CO-NR5R6 ou -CO-NH-R7. Les composés de formule (I) présentent des propriétés pharmacologiques intéressantes. Ces composés sont des antagonistes du récepteur de l'acide $g(a)-amino-3-hydroxy-5-méthyl-4-isoxazolepropionique (AMPA), connu aussi sous le nom de récepteur du quisqualate. Par ailleurs, les composés de formule (I) sont des antagonistes non compétitifs du récepteur N-méthyl-D-aspartate (NMDA) et, plus particulièrement, ce sont des ligands pour les sites modulateurs de la glycine du récepteur NMDA.
    化合物的式子为(I),其中R是氢原子或羧基、烷氧羰基、-CO-NR4R5、-PO3H2或-CH2OH基团,而R1是-烷基-NH2、-烷基-NH-CO-R3、-烷基-COOR4、-烷基-CO-NR5R6或-CO-NH-R7基团。这些式子为(I)的化合物具有有价值的药理学性质,并且是$g(a)-氨基-3-羟基-5-甲基-4-异恶唑丙酸(AMPA)受体的拮抗剂,也被称为喜马拉雅酸受体。此外,这些式子为(I)的化合物是N-甲基-D-天门冬氨酸(NMDA)受体的非竞争性拮抗剂,更具体地说,是NMDA受体甘氨酸调节位点的配体。
  • 1-oxo-1H-inden-2-yl-1H-imidazole-2-carboxylic acid intermediates
    申请人:Rhone-Poulenc Rorer S.A.
    公开号:US06057454A1
    公开(公告)日:2000-05-02
    A compound of formula (II): ##STR1## in which R is a hydrogen atom or a carboxy, alkoxycarbonyl, --CO--NR.sub.4 R.sub.5, --PO.sub.3 H.sub.2 or --CH.sub.2 OH radical, and R.sub.1 is an -alk-NH.sub.2, -alk-NH--CO--R.sub.3, -alk-COOR.sub.4, -alk-CO--NR.sub.5 R.sub.6 or --CO--NH--R.sub.7 radical. The compounds of formula (II) can be used to prepare compounds of formula (I): ##STR2## in which R and R.sub.1 have the same meanings as above. The compounds of formula (I) have valuable pharmacological properties and are antagonists of the .alpha.-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, also known as the quisqualate receptor. The compounds of formula (I) are also non-competitive antagonists of the N-methyl-D-aspartate (NMDA) receptor and more specifically are ligands for NMDA receptor glycine modulator sites.
    式(II)的化合物:##STR1## 其中R是氢原子或羧基,烷氧羰基,--CO--NR.sub.4 R.sub.5,--PO.sub.3 H.sub.2或--CH.sub.2 OH基团,而R.sub.1是-烷基-NH.sub.2,-烷基-NH--CO--R.sub.3,-烷基-COOR.sub.4,-烷基-CO--NR.sub.5 R.sub.6或--CO--NH--R.sub.7基团。式(II)的化合物可用于制备式(I)的化合物:##STR2## 其中R和R.sub.1与上述含义相同。式(I)的化合物具有有价值的药理学特性,并且是α-氨基-3-羟基-5-甲基-4-异恶唑丙酸(AMPA)受体的拮抗剂,也称为石菜酸受体。式(I)的化合物也是N-甲基-D-天门冬氨酸(NMDA)受体的非竞争性拮抗剂,更具体地说是NMDA受体甘氨酸调节剂位点的配体。
  • INDENO[1,2-e]PYRAZINE-4-ONES, LEUR PREPARATION ET LES MEDICAMENTS LES CONTENANT
    申请人:RHONE-POULENC RORER S.A.
    公开号:EP0752991A1
    公开(公告)日:1997-01-15
查看更多

同类化合物

咪唑并[1,2-a]噻吩并[3,2-E]吡嗪-5(4H)-酮 8-羟基咪唑并[1,2-a]吡嗪 5H,10H-二咪唑并[1,2-a:1,2-d]吡嗪-5,10-二酮 5H,10H-二咪唑并[1,2-a:1',5'-d]吡嗪-5,10-二酮 5,6,7,8-四氢-4H-环戊二烯并[E]咪唑并[1,2-a]吡嗪-4-酮 8-(3-benzylureido)-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one 8-(3-butylureido)-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one 8-(3-isopropylureido)-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one 2-nitroimidazo[1,2-a]pyrazin-8(7H)-one 8-(4-methylpentanoyl)amino-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one 3-(10-methyl-4,5-dihydro-4-oxo-10H-imidazo-[1,2-a]indeno[1,2-e]pyrazin-10-yl)propionitrile 10-[(1-methylimidazol-5-yl)methylene]-5H,10H-imidazo[1,2-a]indeno[1,2-e]-pyrazin-4-one hydrochloride 8-(3-tert-butylureido)-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one 8-(3-methylthioureido)-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one 10-formamido-5H,10H-imidazo[1,2-a]indeno[1,2-e]-pyrazin-4-one 10-amino-5H,10H-imidazo[1,2-a]indeno[1,2-e]-pyrazin-4-one hydrochloride 8-hydroxy-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one 8-Methoxy-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one 8-[3-morpholinoureido]-5H,10H-imidazo[1,2-a]indeno[1,2-e]-pyrazine-4-one hydrate 7-chloro-10-methylamino-5H,10H-imidazo-[1,2-a]indeno[1,2-e]pyrazin-4-one hydrochloride 7-chloro-10-formamido-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazin-4-one 10-acetamido-7-chloro-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazin-4-one 10-(2-pyridylmethyl)-5H,10H-imidazo[1,2-a]indeno-[1,2-e]pyrazin-4-one 10-(4-imidazolylmethyl)-5H,10H-imidazo[1,2-a]-indeno[1,2-e]pyrazin-4-one 10-(pyridin-2-ylmethylene)-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazin-4-one 10-(4-imidazolylmethylene)-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazin-4-one 5H,10H-8-aminoimidazo[1,2-a]indeno[1,2-e]pyrazine-4-one monohydrochloride 10-(carboxymethylene)-8-(3-methylureido)-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazin-4-one 8-amino-10-(carboxymethylene)-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazin-4-one dihydrochloride 8-ureido-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one [4,5-dihydro-4-oxo-10H-imidazo[1,2-a]indeno[1,2-e]pyrazin-8-yl]acetic acid 10-(2-methyl-1-propenyl)-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazin-4-one RPR 119990 3-(9-carboxymethyl-4-oxo-5,10-dihydroimidazo[1,2-a]indeno[1,2-e]pyrazin-2-yl]propionic acid 10-[4-(imidazol-1-yl)butyl]-10-methyl-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazin-4-one 12-Methyl-3-thia-1,7,10-triazatricyclo[7.3.0.02,6]dodeca-2(6),4,9,11-tetraen-8-one 3-bromo-7-methyl-imidazo[1,2-a]pyrazin-8-one 5-chloro-7-methyl-8-oxo-6-phenyl-7,8-dihydroimidazo[1,2-a]-pyrazine-3-carbaldehyde ethyl 9-(diethoxyphosphorylmethyl)-4-oxo-5,10-dihydroimidazo[1,2-a]indeno[1,2-e]pyrazine-2-carboxylate ethyl 8-fluoro-4-oxo-4,5-dihydro-10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-2-carboxylate 2-methyl-7H-imidazo[1,2-a]pyrazin-8-one 2-Methyl-7-[(1-phenylcyclopropyl)methyl]imidazo[1,2-a]pyrazin-8-one 3-bromo-2-methyl-7-(1-phenyl-cyclopropylmethyl)-7H-imidazo[1,2-a]pyrazin-8-one 5-chloro-7-(4-methoxybenzyl)-8-oxo-7,8-dihydroimidazo[1,2-a]-pyrazine-3-carbaldehyde 10-hydroxymethylene-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazin-4-one 10-(carboxymethylene)-5H,10H-imidazo[1,2-a]indeno-[1,2-e]pyrazin-4-one 10-(carboxymethyl)-5H,10H-imidazo[1,2-a]indeno[1,2-e]-pyrazin-4-one 8-oxo-7,8-dihydroimidazo[1,2-a]pyrazine hydrochloride 10-amino-5H,10H-imidazo[1,2-a]indeno[1,2-e]-pyrazin-4-one 10-(4-phenylbutyramido)-5H,10H-imidazo[1,2-a]-indeno[1,2-e]pyrazin-4-one